Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-15
2008-12-16
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000
Reexamination Certificate
active
07465740
ABSTRACT:
Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, whereinR is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl;R1is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo;Z is optionally substituted-aryl, or optionally substituted-heteroaryl;are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 6630475 (2003-10-01), Neustadt et al.
patent: 6653315 (2003-11-01), Tulshian et al.
patent: 6897217 (2005-05-01), Neustadt et al.
patent: 7064204 (2006-06-01), Baraldi et al.
patent: 2004/0138235 (2004-07-01), Grzelak et al.
patent: 2005/0239795 (2005-10-01), Neustadt et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO 98/52568 (1998-11-01), None
patent: WO 01/92264 (2001-12-01), None
patent: WO 02/055083 (2002-07-01), None
patent: WO 03/032996 (2003-04-01), None
patent: WO 2004/094431 (2004-11-01), None
patent: WO 2005/044245 (2005-05-01), None
patent: WO 2005/103055 (2005-11-01), None
Golembiowska, K., et al., Striatal Adenosine A2A Receptor Blockade Increases Extracellular Dopamine Release Following L-DOPA Administration in Intact and Dopamine-denervated Rats, Neuropharmacology 47, 414-426 (2004).
M. Saletu et al., Sleep Laboratory Studies in Restless Leg Syndrome Patients as Compared with Normals and Acute Effects of Ropinirole, Neuropsychobiology, 41:4, 190-199 (2000).
International Search Report (PCT/US2006/036127)—5 pages, dated Feb. 6, 2007.
Boyle Craig D.
Chackalamannil Samuel
Harris Joel M.
Lankin Claire M.
Liu Hong
Banerjee Krishna G.
Leeser Erich A
Schering Corporation
Wilson James O.
LandOfFree
2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049188